NASDAQ:IFRX
InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025
InflaRx N.V. surged into today’s session after unveiling topline Phase 2a data for its oral C5aR inhibitor INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, alongside filing its third‑quarter Form 6‑K showing €44.4 million…
Company hubNASDAQ:IFRX
IFRX (IFRX) Stock News & Analysis
Follow the latest IFRX (IFRX) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 1
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
All coverage